Evidence map›Paper›PMID 28360514›Full record

SynthesisInternational journal of chronic obstructive pulmonary disease2017

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Gustavo J Rodrigo, David Price, Antonio Anzueto, Dave Singh, Pablo Altman, Giovanni Bader, Francesco Patalano, Robert Fogel, Konstantinos Kostikas

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 11 pooled it
18.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 11 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Inhaled corticosteroids and FEVRespiratory research · 2019
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review.International journal of chronic obstructive pulmonary disease
    Pooled it
  11. LABA/LAMA fixed-dose combinationsTherapeutic advances in respiratory disease
    Pooled it
  12. Trial
  13. Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.International journal of chronic obstructive pulmonary disease
    Trial
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 5 countries.

Gustavo J RodrigoDepartamento de Emergencia, Hospital Central de las Fuerzas Armadas, Montevideo, Uruguay.
David PriceAcademic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, UK; Observational and Pragmatic Research Institute, Singapore.
Antonio AnzuetoUniversity of Texas Health Science Center; South Texas Veterans Health Care System, San Antonio, TX, USA.
Dave SinghMedicines Evaluation Unit, National Institute for Health Research Respiratory and Allergy Clinical Research Facility, University Hospital of South Manchester NHS Foundation Trust, University of Manchester, Manchester, England, UK.
Pablo AltmanNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Giovanni BaderNovartis Pharma AG, Basel, Switzerland.
Francesco PatalanoNovartis Pharma AG, Basel, Switzerland.
Robert FogelNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Konstantinos KostikasNovartis Pharma AG, Basel, Switzerland.
Novartis (Switzerland) · CHNovartis (United States) · USHospital Central de las Fuerzas Armadas · UYMedicines Evaluation Unit · GBThe University of Texas Health Science Center at San Antonio · USUniversity of Aberdeen · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRandomized controlled trials (RCTs) indicate that long-acting bronchodilator combinations, such as β

methodsThis systematic review and meta-analysis (PubMed/MEDLINE, Embase, Cochrane Library and clinical trial/manufacturer databases) included RCTs comparing ≥12 weeks' LABA/LAMA treatment with LAMA and/or LABA/ICS (approved doses only). Eligible studies were independently selected by two authors using predefined data fields; the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed.

resultsEighteen studies (23 trials) were eligible (N=20,185). LABA/LAMA significantly improved trough forced expiratory volume in 1 second (FEV

conclusionThe greater efficacy and comparable safety profiles observed with LABA/LAMA combinations versus LAMA or LABA/ICS support their potential role as first-line treatment options in COPD. These findings are of direct relevance to clinical practice because we included all currently available LABA/LAMAs and comparators, only at doses approved for clinical use.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsChi-Square DistributionDisease ProgressionDrug CombinationsForced Expiratory VolumeHumansLungMuscarinic AntagonistsOdds RatioPulmonary Disease, Chronic ObstructiveRandomized Controlled Trials as TopicRecovery of FunctionRisk FactorsAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsMuscarinic AntagonistsCOPDLABA/ICSLABA/LAMA combinationsLAMAmeta-analysis

Identifiers

PMID28360514
PMCPMC5364009
OpenAlexW2596492194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.